GU Cancers 2023 | Exciting times for hormone-sensitive prostate cancer treatment

Kamal Sahu, MBBS, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, highlights soon-to-be-published results in the field of prostate cancer. Dr Sahu notes that drugs previously approved in the hormone-resistant setting are now being tested in hormone-sensitive prostate cancer. Rucaparib, olaparib, and talazoparib are some of the drugs previously tested in the castration-resistant setting that are currently undergoing trials in the hormone-sensitive setting. Talapro-3 (NCT04821622) and AMPLITUDE (NCT04497844) are two trials with potentially exciting results for hormone-sensitive treatment in 2024. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.